Navigation Links
HUYA Bioscience Int'l Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
Date:3/3/2008

sors (announced in a separate release) for HBI-3000 comprise a world class team of scientists and clinicians including Benedict Lucchesi, Ph.D. MD, Peter R. Kowey, M.D., Dennis Roy, M.D., Jefferson L. Anderson, M.D., Eric J. Topol, M.D., and Stanley Nattel, M.D.

About HUYA

HUYA is the leader in U.S./China pharmaceutical co-development, formed to meet the global need for new, untapped sources of pre-clinical and clinical stage compounds. HUYA identifies the most promising new compounds in China and partners with Chinese research institutions to leverage and extend their research efforts, accelerate development, and provide a bridge into the U.S. development process and the biopharma market. With three strategic offices in China, the broadest Chinese compound portfolio, and more exclusive agreements with premier Chinese biotech centers than any other company, HUYA has pioneered the most innovative and productive approach for pharmaceutical co-development between the U.S and China. Further information about the company is available at http://www.huyabio.com.

Contact:

USA:

Jan Tuttleman, Ph.D.

Vice President, Marketing

HUYA Bioscience International

(858) 798-8800

jtuttleman@huyabio.com

China:

Wen Chen, M.S., MBA

EVP China Operation and Chief Representative

HUYA Bioscience International

86 (21) 51323312

wchen@huyabio.com

Media Contacts:

Amy Berry

(415) 793-2258

amyeberry@comcast.net

Juliet Travis

(510) 452-3771

juliet@travispr.com


'/>"/>
SOURCE HUYA Bioscience International
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments
2. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
3. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
4. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
5. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
6. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
7. Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis
8. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
9. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
10. Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , August 28, 2014 ... Market Research "Radiofrequency Identification (RFID) Market (Tags, Readers, Middleware, ... Growth, Trends and Forecast, 2014 - 2020" the global ... billion in 2013 and is expected to grow at ... reach an estimated value of USD 5.3 billion in ...
(Date:8/28/2014)... -- In recognition of the increased risks that seniors ... pneumonia, shingles and other illnesses, CVS/pharmacy ® ... be Senior Vaccination Month. Because people,s immune systems ... adults ages 65 years and older stay up ... MinuteClinic nurse practitioners and physician assistants will be ...
(Date:8/28/2014)... , Aug. 28, 2014   Venaxis, Inc.  (Nasdaq: ... on obtaining FDA clearance for and commercializing its CE ... for aiding in identifying children, adolescent, and young adult ... risk for appendicitis, today announced it will present at ... th Annual Global Investment Conference being held in ...
Breaking Medicine Technology:Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 2Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 3Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 4Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 5September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 2September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 3September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 4Venaxis to Present at September Investor Conferences 2Venaxis to Present at September Investor Conferences 3
... CHAPEL HILL, N.C., US, March 06, 2007,/PRNewswire/ ... and,Lantibio, Inc. ("Lantibio") today announced positive final ... clinical,study of Moli1901, an experimental compound to ... by AOP Orphan in,Europe under a licensing ...
... 7, 2007 - BioLineRx Ltd.,(TASE:BLRX), Israel's leading ... trials of BL-1040 demonstrating that,BL-1040 is effective ... myocardial infarction (MI), thereby reducing left ventricle,dilatation ... model. Professor,Jonathan Leor, MD, Director of the ...
Cached Medicine Technology:AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II,Study with Novel Cystic Fibrosis Therapy 2AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II,Study with Novel Cystic Fibrosis Therapy 3AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II,Study with Novel Cystic Fibrosis Therapy 4BioLineRx Presents Data on BL-1040 at Cardiovascular,Revascularization Therapies Conference Demonstrating Potential to,Reduce Deterioration of Infarcted Heart Tissue and Maintain,Functionality 2BioLineRx Presents Data on BL-1040 at Cardiovascular,Revascularization Therapies Conference Demonstrating Potential to,Reduce Deterioration of Infarcted Heart Tissue and Maintain,Functionality 3
(Date:8/28/2014)... Lake Worth, FL (PRWEB) August 28, 2014 ... promote National Recovery Month throughout September. This month ... of addiction treatment and mental health services. Along ... Millennium Treatment Group is helping to spread the ... Month began in 1989, honoring the work of ...
(Date:8/28/2014)... Tempe, Ariz. (PRWEB) August 28, 2014 ... Force Impact Technologies , has been named one ... of the Year competition. , This is the fourth ... finalist in the competition. Jared Schoepf, co-founder of SafeSIPP, ... in 2013 and 2012, respectively. In 2011, ASU dominated ...
(Date:8/28/2014)... American adults who are beginning to research ... now have a simpler way to connect with companies ... year, some of the best life insurance rates available ... The promoted plans that included price data revealed to ... policies. The term, guaranteed and modified plans that might ...
(Date:8/28/2014)... HealthDay Reporter THURSDAY, Aug. 28, 2014 (HealthDay ... symptoms of multiple sclerosis (MS), a new study from Argentina ... D, smoking and Epstein Barr virus infection. Our study shows ... MS patients," said lead researcher Dr. Mauricio Farez, of the ... Multiple sclerosis is a disease of the nervous system that ...
(Date:8/28/2014)... ABC television stars will join forces this Labor Day ... airing Sunday, Aug. 31, 9/8c on ABC television stations ... to help save and improve the lives of children ... into the 2014 telethon to benefit the Muscular Dystrophy ... of the network’s leading stars, including Alyssa Milano of ...
Breaking Medicine News(10 mins):Health News:Millennium Treatment Group Celebrates National Recovery Month 2Health News:Arizona State University Grad Student in the Running for College Entrepreneur of the Year 2Health News:Arizona State University Grad Student in the Running for College Entrepreneur of the Year 3Health News:Best Life Insurance Rates for 2014 Now Promoted at Insurer Website 2Health News:Could Too Much Salt Harm MS Patients? 2Health News:Could Too Much Salt Harm MS Patients? 3Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 2Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 3Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 4
... , , , ... Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic and services ... NewCardio,s QTinno(TM) software suite, NewCardio,s first commercial product, as the ... automated Thorough QT (TQT) studies. , , ...
... , , SAO PAULO, July 30 ... Healthcare is the recipient of the 2009 ... Market. Agfa offers a complete portfolio of solutions including ... CR market, as perceived by the needs of customers willing to ...
... ($ millions, except per-share amounts), ... % Change, ... ... $243 $199 22%, Diluted EPS from Continuing Operations ...
... ... in flexible design with custom mounting, shafts, and low noise plastic and steel gearing options. ... Chatsworth, CA (PRWEB) -- ... planetary gearboxes. These are specially design for the medical industry, as well as for pumps, ...
... ... that it has teamed with Patrick Rummerfield, the first fully functional quadriplegic ... proceeds of the upcoming Golf Classic Tournament to the rehabilitation of an ... have also stepped in to donate a state of the art Functional ...
... ... a less expensive education in the thriving nursing industry. , ... Seattle, Washington (PRWEB) July 30, 2009 -- ... qualified nurse, and online nursing degrees are becoming a popular and effective way to ...
Cached Medicine News:Health News:Top-Five Global Pharmaceutical Company Names NewCardio as its Provider of Automated Thorough QT Solution 2Health News:Top-Five Global Pharmaceutical Company Names NewCardio as its Provider of Automated Thorough QT Solution 3Health News:Top-Five Global Pharmaceutical Company Names NewCardio as its Provider of Automated Thorough QT Solution 4Health News:Frost & Sullivan Awards Agfa Healthcare for Brazilian Market Penetration Leadership in 2009 2Health News:Frost & Sullivan Awards Agfa Healthcare for Brazilian Market Penetration Leadership in 2009 3Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 2Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 3Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 4Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 5Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 6Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 7Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 8Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 9Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 10Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 11Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 12Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 13Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 14Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 15Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 16Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 17Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 18Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 19Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 20Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 21Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 22Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 23Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 24Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 25Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 26Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 27Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 28Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 29Health News:New Custom Hybrid Planetary Gearbox Series from NMB 2Health News:Patrick Rummerfield Teams with Eric Westacott Foundation and Christopher and Dana Reeve Foundation to Help Young Quadriplegic Boy 2
... specifically for detection of recent-onset neovascular ("wet") ... maps and quantifies visual field defects consistent ... to the wet stage of the disease. ... for small visual field defects, the PreView ...
... a new functional test which exhibits 100% ... C Resistance caused by the Factor V ... commercially available methods, Pefakit APC-R FVL shows ... Lupus Anticoagulants, Elevated FVIII levels, Heparins or ...
Cable connections for 5 different adapters: Storz, ACMI, Pentax, Wolf and Olympus....
Lightweight PVC housing for easy transport, integrated handle. Easy lamp exchange....
Medicine Products: